EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial

Oriol Manuel iD, Mirjam Laager, Cédric Hirzel, Dionysios Neofytos, Laura N Walti, Gideon Hoenger, Isabelle Binet, Aurelia Schnyder, Susanne Stampf, Michael Koller, Matteo Mombelli, Min Jeong Kim und 27 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad575 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Oriol Manuel und 38 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Organ Transplantation. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of assays detecting cytomegalovirus (CMV)–specific T cell–mediated immunity may individualize the duration of antiviral prophylaxis after transplantation.

Methods

In this randomized trial, kidney and liver transplant recipients from 6 centers in Switzerland were enrolled if they were CMV-seronegative with seropositive donors or CMV-seropositive receiving antithymocyte globulins. Patients were randomized to a duration of antiviral prophylaxis based on immune monitoring (intervention) or a fixed duration (control). Patients in the control group were planned to receive 180 days (CMV-seronegative) or 90 days (CMV-seropositive) of valganciclovir. Patients were assessed monthly with a CMV ELISpot assay (T-Track CMV); prophylaxis in the intervention group was stopped if the assay was positive. The co-primary outcomes were the proportion of patients with clinically significant CMV infection and reduction in days of prophylaxis. Between-group differences were adjusted for CMV serostatus.

Results

Overall, 193 patients were randomized (92 in the immune-monitoring group and 101 in the control group), of whom 185 had evaluation of the primary outcome (87 and 98 patients). CMV infection occurred in 26 of 87 (adjusted percentage, 30.9%) in the immune-monitoring group and in 32 of 98 (adjusted percentage, 31.1%) in the control group (adjusted risk difference, −0.1; 95% confidence interval [CI], −13.0% to 12.7%; P = .064). The duration of prophylaxis was shorter in the immune-monitoring group (adjusted difference, −26.0 days; 95%, CI, −41.1 to −10.8 days; P < .001).

Conclusions

Immune monitoring resulted in a significant reduction of antiviral prophylaxis, but we were unable to establish noninferiority of this approach on the co-primary outcome of CMV infection. Clinical Trials Registration NCT02538172.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsOrgan TransplantationHumansCytomegalovirusAntiviral AgentsMonitoring, ImmunologicTransplant RecipientsGanciclovir

Stichwörter der Autor:innen

cell-mediated immunitypersonalized medicinepreventiontransplantviral infection

Substanzen

Antiviral AgentsGanciclovir

Autor:innen und Institutionen

  • Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Transplantation Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland.
  • Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Transplant Infectious Diseases Unit, University Hospitals Geneva and Faculty of Medicine, Geneva, Switzerland.
  • Department of Biomedicine, Immunobiology, University of Basel and University Hospital of Basel, Basel, Switzerland.

ORCID-Profile: Oriol Manuel

Zitieren

APA

Manuel, O., Laager, M., Hirzel, C., Neofytos, D., Walti, L. N., Hoenger, G., Binet, I., Schnyder, A., Stampf, S., Koller, M., Mombelli, M., Kim, M. J., Hoffmann, M., Koenig, K., Hess, C., Burgener, A. V., Cippà, P. E., Hübel, K., Mueller, T. F., …, & Swiss Transplant Cohort Study (STCS) (2024). Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad575

Vancouver

Manuel O, Laager M, Hirzel C, Neofytos D, Walti LN, Hoenger G, et al. Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad575

BibTeX
@article{Manuel2024,
  author = {Manuel, Oriol and Laager, Mirjam and Hirzel, Cédric and Neofytos, Dionysios and Walti, Laura N and Hoenger, Gideon and Binet, Isabelle and Schnyder, Aurelia and Stampf, Susanne and Koller, Michael and Mombelli, Matteo and Kim, Min Jeong and Hoffmann, Matthias and Koenig, Katrin and Hess, Christoph and Burgener, Anne-Valérie and Cippà, Pietro E and Hübel, Kerstin and Mueller, Thomas F and Sidler, Daniel and Dahdal, Suzan and Suter-Riniker, Franziska and Villard, Jean and Zbinden, Andrea and Pantaleo, Giuseppe and Semmo, Nasser and Hadaya, Karine and Enríquez, Natalia and Meylan, Pascal R and Froissart, Marc and Golshayan, Dela and Fehr, Thomas and Huynh-Do, Uyen and Pascual, Manuel and van Delden, Christian and Hirsch, Hans H and Jüni, Peter and Mueller, Nicolas J and Swiss Transplant Cohort Study (STCS), Swiss Transplant Cohort Study (STCS)},
  title = {Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad575}
}
Kostenlos starten →